Arovella Therapeutics Limited

ASX:ALA Stock Report

Mkt Cap: AU$23.4m

Arovella Therapeutics Future Growth

How is Arovella Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

55.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

ASX:ALA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20257N/AN/AN/A1
6/30/20245-2N/AN/A2
6/30/20232-6N/AN/A2
6/30/20220-9-7-6N/A
3/31/20220-8-6-5N/A
12/31/20211-7-4-4N/A
9/30/20211-6-4-4N/A
6/30/20211-5-4-4N/A
3/31/20211-5-4-3N/A
12/31/202012-3-3N/A
9/30/20201-1-3-3N/A
6/30/20201-4-3-3N/A
3/31/20201-12-4-3N/A
12/31/20191-15-4-3N/A
9/30/20191-11-4-3N/A
6/30/20191-8-4-2N/A
3/31/20191-6-4-3N/A
12/31/20181-5-4-3N/A
9/30/20181-5-4-3N/A
6/30/20180-6-3-3N/A
3/31/20185-4-3-2N/A
12/31/20171-3-2-1N/A
9/30/20171-2-2-1N/A
6/30/20171-1-2-1N/A
3/31/20174-1-2-1N/A
12/31/20163-1-2-1N/A
9/30/20165-2-3-1N/A
6/30/20166-2-3-2N/A
3/31/20166-3N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALA's revenue (45.4% per year) is forecast to grow faster than the Australian market (3.6% per year).

High Growth Revenue: ALA's revenue (45.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALA's Return on Equity is forecast to be high in 3 years time

Discover growth companies